These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 33665728)
1. Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach. Zhang Y; Liu H; Tang MJ; Ho NJ; Shek TL; Yang Z; Zuo Z AAPS J; 2021 Mar; 23(2):38. PubMed ID: 33665728 [TBL] [Abstract][Full Text] [Related]
2. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation. Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538 [TBL] [Abstract][Full Text] [Related]
3. Bioequivalence of Related GelShield Krebs-Brown A; Brand KMG; Filho MAFN; Gaikwad S; Schnaars Y Clin Ther; 2024 May; 46(5):389-395. PubMed ID: 38688745 [TBL] [Abstract][Full Text] [Related]
4. Novel extended IVIVC combined with DoE to predict pharmacokinetics from formulation compositions. Lim JY; Kim TH; Song CH; Kim DH; Shin BS; Shin S J Control Release; 2022 Mar; 343():443-456. PubMed ID: 35124130 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate. Kesisoglou F; Xia B; Agrawal NG AAPS J; 2015 Nov; 17(6):1492-500. PubMed ID: 26290380 [TBL] [Abstract][Full Text] [Related]
6. A Semi-Mechanistic Physiologically Based Biopharmaceutics Model to Describe Complex and Saturable Absorption of Metformin: Justification of Dissolution Specifications for Extended Release Formulation. Bhattiprolu AK; Kollipara S; Boddu R; Arumugam A; Khan SM; Ahmed T AAPS PharmSciTech; 2024 Aug; 25(7):193. PubMed ID: 39168956 [TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Timmins P; Donahue S; Meeker J; Marathe P Clin Pharmacokinet; 2005; 44(7):721-9. PubMed ID: 15966755 [TBL] [Abstract][Full Text] [Related]
8. Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. Boulton DW; Chang M; Griffen SC; Kitaura C; Lubin S; Pollack A; LaCreta F Clin Ther; 2016 Jan; 38(1):99-109. PubMed ID: 26682500 [TBL] [Abstract][Full Text] [Related]
9. In Vitro Dissolution and In Vivo Bioequivalence Evaluation of Two Metformin Extended-Release Tablets. Zhou Z; Wang C; Li M; Lan Q; Yu C; Yu G; Xia Y; Chen H; Zhang X Clin Pharmacol Drug Dev; 2021 Apr; 10(4):414-419. PubMed ID: 32706921 [TBL] [Abstract][Full Text] [Related]
10. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Jantratid E; Prakongpan S; Amidon GL; Dressman JB Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285 [TBL] [Abstract][Full Text] [Related]
11. Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data. Mittapalli RK; Marroum P; Qiu Y; Apfelbaum K; Xiong H Pharm Res; 2017 Jul; 34(7):1527-1533. PubMed ID: 28512718 [TBL] [Abstract][Full Text] [Related]
12. Prediction of in vivo performance of oral extended release formulations prior to clinical evaluation: A case study for enteric coated polymeric beads formulation. Xu J; Lin Y; Zawaneh PN; Nestorov I; Leung CY; Boulas P Eur J Pharm Biopharm; 2021 Jan; 158():222-232. PubMed ID: 33279603 [TBL] [Abstract][Full Text] [Related]
13. In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers. Balan G; Timmins P; Greene DS; Marathe PH J Pharm Sci; 2001 Aug; 90(8):1176-85. PubMed ID: 11536222 [TBL] [Abstract][Full Text] [Related]
14. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. Chen C; Bujanover S; Kareht S; Rapoport AM Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369 [TBL] [Abstract][Full Text] [Related]
15. In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC. Ruiz Picazo A; Martinez-Martinez MT; Colón-Useche S; Iriarte R; Sánchez-Dengra B; González-Álvarez M; García-Arieta A; González-Álvarez I; Bermejo M Mol Pharm; 2018 Jun; 15(6):2307-2315. PubMed ID: 29746133 [TBL] [Abstract][Full Text] [Related]
16. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model. Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663 [TBL] [Abstract][Full Text] [Related]
17. Development of a level A in vitro-in vivo correlation for extended release dosage forms of quetiapine fumarate. Gonçalves de Lima L; Rossi de Campos D Drug Res (Stuttg); 2016 May; 66(5):225-9. PubMed ID: 26697891 [TBL] [Abstract][Full Text] [Related]
18. Comparative Bioavailability of Metformin Hydrochloride Oral Solution Versus Metformin Hydrochloride Tablets in Fasting Mexican Healthy Volunteers. Garza-Ocañas L; González-Canudas J; Tamez-de la O E; Badillo-Castañeda C; Gómez-Meza MV; Romero-Antonio Y; Molina-Pérez A; Amador-Hernández AG Adv Ther; 2019 Feb; 36(2):407-415. PubMed ID: 30565181 [TBL] [Abstract][Full Text] [Related]
19. Convolution-based approaches for in vivo-in vitro correlation modeling. Gillespie WR Adv Exp Med Biol; 1997; 423():53-65. PubMed ID: 9269483 [TBL] [Abstract][Full Text] [Related]
20. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests. Yamaguchi Ikeuchi S; Kambayashi A; Kojima H; Oku N; Asai T Biol Pharm Bull; 2018; 41(11):1708-1715. PubMed ID: 30381671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]